Abivax is a clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with inflammatory diseases, viral infections, and cancer. The company develops therapies that stimulate the body’s natural immune system machinery. Abivax aims to use its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Year of creation: 2013
Line of business: Biopharmaceutics
Institut Curie: Technology-based and R&D partner
Abivax leverages three technology platforms for drug discovery.
1. ABX464: Modulation of RNA Biogenesis
Abivax developed ABX464 from the company’s chemical library of over 2,200 small molecules that have the potential to modulate RNA splicing. The resulting effects of ABX464's RNA splicing constitute a potent anti-inflammatory action, as well as an ability to reduce viral reservoirs of HIV.
2. ABX196: Immune Enhancement
Abivax is developing ABX196, an immune enhancer for the combination treatment of hepatocellular carcinoma (HCC) with a check point inhibitor. HCC is the most common type of primary liver cancer. The company’s technology focuses on invariant natural killer T-cells (iNKT) to fight tumors.
3. ABX544: Polyclonal Antibody
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464), COVID-19 (ABX464), HIV (ABX464), and liver cancer (ABX196).
Abivax is advancing multiple preclinical candidates for the treatment of additional inflammatory diseases as well as viral infections such as Respiratory Syncytial Virus (RSV), Dengue, and Influenza from its Modulation of RNA Biogenesis platform and several of these compounds could enter clinical development before 202.
More about Abivax: